IPO Pro - "The Ultimate Resource for IPOs"
Don't risk buying another IPO without IPO Pro.
Get your FREE TRIAL now.
Phase 2 biotech developing targeted therapies for cancer in genomically-defined patients.
Industry: Health Care
Latest Trade: $3.79 +0.17 (+4.7%)
First Day Return: -28.5%
Return from IPO: -77.4%
Industry: Health Care
IPO Data | |
---|---|
IPO File Date | 06/04/2021 |
Offer Price | $16.00 |
Price Range $15.00 - $17.00 | |
Offer Shares (mm) | 6.3 |
Deal Size ($mm) | $100 |
Lock-Up Date | IPO Pro Only |
Street Research | IPO Pro Only |
IPO Data | |
---|---|
IPO Date | 06/24/2021 |
Offer Price | $16.00 |
Price Range $15.00 - $17.00 | |
Offer Shares (mm) | 6.3 |
Deal Size ($mm) | $100 |
Lock-Up Date | IPO Pro Only |
Street Research | IPO Pro Only |
Underwriters |
---|
J.P. Morgan |
TD Cowen |
more |
Company Data | |
---|---|
Headquarters | New York, NY, United States |
Founded | 2019 |
Employees | 8 |
Website elevationoncology.com |